(Q48509763)

12 February 2018

title

Symptom management in patients with multiple sclerosis. (English)

1 reference

12 February 2018

0 references

1

1 reference

12 February 2018

publication date

1 December 2011

1 reference

12 February 2018

Journal of the Neurological Sciences

published in

1 reference

12 February 2018

volume

311 Suppl 1

1 reference

12 February 2018

page(s)

S48-52

1 reference

12 February 2018

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Depression and quality of life in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

A multimodal approach to managing the symptoms of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Major depression in multiple sclerosis: a population-based perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Depression and multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Multiple sclerosis beyond EDSS: depression and fatigue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Treatment of fatigue in multiple sclerosis: a systematic review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

One question as a screening instrument for depression in people with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Sexual dysfunction in multiple sclerosis: a 2-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Immunologically mediated fatigue: A murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Brain-immune communication psychoneuroimmunology of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Endocrine and cytokine responses to acute psychological stress in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Chronic fatigue syndrome--aetiological aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Treatment of depression for patients with multiple sclerosis in neurology clinics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

Rehabilitation and multiple sclerosis: hot topics in the preservation of physical functioning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970009-0

10.1016/S0022-510X(11)70009-0

7 January 2021

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018